Carbonate apatite-facilitated intracellularly delivered siRNA for efficient knockdown of functional genes

Journal of Controlled Release

Volumn 147, Issue 1, 2010, Pages 101-108

  Hossain, Sharif ^a   Stanislaus, Anthony ^b   Chua, Ming Jang ^b   Tada, Seiichi ^a   Tagawa, Yoh ichi ^a   Chowdhury, Ezharul Hoque ^a,b   Akaike, Toshihiro ^a  

^a TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^b INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

Author keywords

Apoptosis; Cancer cell; Carbonate apatite; Cyclin B1; Gene silencing; SiRNA

Indexed keywords

APOPTOSIS; CANCER CELL; CARBONATE APATITE; CYCLIN B1; GENE SILENCING; SIRNA;

APATITE; CARBONATION; CELL DEATH; DISEASE CONTROL; GENETIC ENGINEERING; MAMMALS; MOLECULAR BIOLOGY; PHOSPHATE MINERALS; RNA;

GENE THERAPY;

APATITE; CARBONIC ACID; CYCLIN B1; GREEN FLUORESCENT PROTEIN; LIPOFECTAMINE; LUCIFERASE; NANOPARTICLE; SMALL INTERFERING RNA;

ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER INHIBITION; CELL DEATH; CELL INTERACTION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; ENDOSOME; GENE EXPRESSION; GENE SILENCING; HELA CELL; HUMAN; HUMAN CELL; LIGHT SCATTERING; MAMMAL CELL; PH MEASUREMENT; PRIORITY JOURNAL; REPORTER GENE; TRANSMISSION ELECTRON MICROSCOPY;

APATITES; CELL SURVIVAL; CLONING, MOLECULAR; CYTOMEGALOVIRUS; DRUG CARRIERS; DRUG COMPOUNDING; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HELA CELLS; HUMANS; MICROSCOPY, ELECTRON, TRANSMISSION; MICROSCOPY, FLUORESCENCE; PARTICLE SIZE; PLASMIDS; RNA, SMALL INTERFERING; SOLUBILITY; SURFACE PROPERTIES;

EID: 77956552507     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.06.024     Document Type: Article

References (59)

1. Winkler J., Martin-Killias P., Plückthun A. U Zangemeister-Wittke, EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins. Mol. Cancer Ther. 2009, 8:2674-2683.
2. de Fougerolles A.R. Delivery vehicles for small interfering RNA in vivo. Hum. Gene Ther. 2008, 19:125-132.
3. Gao K., Huang L. Nonviral methods for siRNA delivery. Mol. Pharm. 2009, 6:651-658.
4. Lee N.S., Rossi J.J. Control of HIV-1 replication by RNA interference. Virus Res. 2004, 102:53-58.
5. Grünweller A., Hartmann R.K. RNA interference as a gene-specific approach for molecular medicine. Curr. Med. Chem. 2005, 12:3143-3161.
6. Ito M., Kawano K., Miyagishi M., Taira K. Genome-wide application of RNAi to the discovery of potential drug targets. FEBS Lett. 2005, 579:5988-5995.
7. Lu P.Y., Xie F., Woodle M.C. In vivo application of RNA interference: from functional genomics to therapeutics. Adv. Genet. 2005, 54:117-142.
8. Chowdhury E.H. Nuclear targeting of viral and non-viral DNA. Expert Opin. Drug Deliv. 2009, 6:697-703.
9. Reischl D., Zimmer A. Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. Nanomedicine 2009, 5:8-20.
10. Amarzguioui M., Rossi J.J., Kim D. Approaches for chemically synthesized siRNA and vector-mediated RNAi. FEBS Lett. 2005, 579:5974-5981.
11. Scherr M., Eder M. Gene silencing by small regulatory RNAs in mammalian cells. Cell Cycle 2007, 6:444-449.
12. Buyens K., Meyer M., Wagner E., Demeester J., De Smedt S.C., Sanders N.N. Monitoring the disassembly of siRNA polyplexes in serum is crucial for predicting their biological efficacy. J. Control. Release 2009, 141:38-41.
13. Dobbs W., Heinrich B., Bourgogne C., Donnio B., Terazzi E., Bonnet M.E., Stock F., Erbacher P., Bolcato-Bellemin A.L., Douce L. Mesomorphic Imidazolium salts: new vectors for efficient siRNA transfection. J. Am. Chem. Soc. 2009, 131:13338-13346.
14. Delong R.K., Akhtar U., Sallee M., Parker B., Barber S., Zhang J., Craig M., Garrad R., Hickey A.J., Engstrom E. Characterization and performance of nucleic acid nanoparticles combined with protamine and gold. Biomaterials 2009, 30:6451-6459.
15. Liu C., Zhao G., Liu J., Ma N., Chivukula P., Perelman L., Okada K., Chen Z., Gough D., Yu L. Novel biodegradable lipid nano complex for siRNA delivery significantly improving the chemosensitivity of human colon cancer stem cells to paclitaxel. J. Control. Release 2009, 140:277-283.
16. Cho H.A., Park I.S., Kim T.W., Oh Y.K., Yang K.S., Kim J.S. Suppression of hepatitis B virus-derived human hepatocellular carcinoma by NF-kappaB-inducing kinase-specific siRNA using liver-targeting liposomes. Arch. Pharm. Res. 2009, 32:1077-1086.
17. Merkel O.M., Beyerle A., Librizzi D., Pfestroff A., Behr T.M., Sproat B., Barth P.J., Kissel T. Nonviral siRNA delivery to the lung: investigation of PEG-PEI polyplexes and their in vivo performance. Mol. Pharm. 2009, 6:1246-1260.
18. MacDiarmid J.A., Amaro-Mugridge N.B., Madrid-Weiss J., Sedliarou I., Wetzel S., Kochar K., Brahmbhatt V.N., Phillips L., Pattison S.T., Petti C., Stillman B., Graham R.M., Brahmbhatt H. Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat. Biotechnol. 2009, 27:643-651.
19. Mangala L.S., Han H.D., Lopez-Berestein G., Sood A.K. Liposomal siRNA for ovarian cancer. Meth. Mol. Biol. 2009, 555:29-42.
20. Jere D., Jiang H.L., Kim Y.K., Arote R., Choi Y.J., Yun C.H., Cho M.H., Cho C.S. Chitosan-graft-polyethylenimine for Akt1 siRNA delivery to lung cancer cells. Int. J. Pharm. 2009, 378:194-200.
21. Crombez L., Morris M.C., Dufort S., Aldrian-Herrada G., Nguyen Q., Mc Master G., Coll J.L., Heitz F., Divita G. Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth. Nucleic Acids Res. 2009, 37:4559-4569.
22. Difeo A., Huang F., Sangodkar J., Terzo E.A., Leake D., Narla G., Martignetti J.A. KLF6-SV1 is a novel antiapoptotic protein that targets the BH3-only protein NOXA for degradation and whose inhibition extends survival in an ovarian cancer model. Cancer Res. 2009, 69:4733-4741.
23. Ponnappa B.C. siRNA for inflammatory diseases. Curr. Opin. Investig. Drugs 2009, 10:418-424.
24. Oh Y.K., Park T.G. siRNA delivery systems for cancer treatment. Adv. Drug Deliv. Rev. 2009, 61:850-862.
25. Mu P., Nagahara S., Makita N., Tarumi Y., Kadomatsu K., Takei Y. Systemic delivery of siRNA specific to tumor mediated by atelocollagen: combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer. Int. J. Cancer 2009, 125:2978-2990.
26. Al-Abd A.M., Lee S.H., Kim S.H., Cha J.H., Park T.G., Lee S.J., Kuh H.J., et al. Penetration and efficacy of VEGF siRNA using polyelectrolyte complex micelles in a human solid tumor model in-vitro. J. Control. Release 2009, 137:130-135.
27. Koldehoff M., Elmaagacli A.H. Therapeutic targeting of gene expression by siRNAs directed against BCR-ABL transcripts in a patient with imatinib-resistant chronic myeloid leukaemia. Meth. Mol. Biol. 2009, 487:451-466.
28. Wang X.L., Xu R., Wu X., Gillespie D., Jensen R., Lu Z.R. Targeted systemic delivery of a therapeutic siRNA with a multifunctional carrier controls tumor proliferation in mice. Mol. Pharm. 2009, 6:738-746.
29. Davis M.E. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol. Pharm. 2009, 6:659-668.
30. Tseng Y.C., Mozumdar S., Huang L. Lipid-based systemic delivery of siRNA. Adv. Drug Deliv. Rev. 2009, 61:721-731.
31. Grzelinski M., Urban-Klein B., Martens T., Lamszus K., Bakowsky U., Höbel S., Czubayko F., Aigner A. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum. Gene Ther. 2006, 17:751-766.
32. Engelhardt J.F., Simon R.H., Yang Y., Zepeda M., Weber-Pendleton S., Doranz B., Grossman M., Wilson J.M. Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: biological efficacy study. Hum. Gene Ther. 1993, 4:759-769.
33. Lehrman S. Virus treatment questioned after gene therapy death. Nature 1999, 401:517-518.
34. Zimmermann T.S., Lee A.C., Akinc A., Bramlage B., Bumcrot D., Fedoruk M.N., Harborth J., Heyes J.A., Jeffs L.B., John M., Judge A.D., Lam K., McClintock K., Nechev L.V., Palmer L.R., Racie T., Röhl I., Seiffert S., Shanmugam S., Sood V., Soutschek J., Toudjarska I., Wheat A.J., Yaworski E., Zedalis W., Koteliansky V., Manoharan M., Vornlocher H.P., MacLachlan I. RNAi-mediated gene silencing in non-human primates. Nature 2006, 441:111-114.
35. Fattal E., Barratt G. Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA. Br. J. Pharmacol. 2009, 157:179-194.
36. Kim W.J., Kim S.W. Efficient siRNA delivery with non-viral polymeric vehicles. Pharm. Res. 2009, 26:657-666.
37. Akhtar S., Hughes M.D., Khan A., Bibby M., Hussain M., Nawaz Q., Double J., Sayyed P. The delivery of antisense therapeutics. Adv. Drug Deliv. Rev. 2000, 44:3-21.
38. Nakamura Y., Kogure K., Futaki S., Harashima H. Octaarginine-modified multifunctional envelope-type nano device for siRNA. J. Control. Release 2007, 119(3):360-367.
39. Luo D., Saltzman W.M. Synthetic DNA delivery systems. Nat. Biotechnol. 2000, 18:33-37.
40. Ganta S., Devalapally H., Shahiwala A., Amiji M. A review of stimuli-responsive nanocarriers for drug and gene delivery. J. Control Release 2008, 126:187-204.
41. Hossain S., Tada S., Akaike T., Chowdhury E.H. Influences of electrolytes and glucose on formulation of carbonate apatite nanocrystals for efficient gene delivery to mammalian cells. Anal. Biochem. 2010, 397:156-161.
42. Chowdhury E.H., Maruyama A., Kano A., Nagaoka M., Kotaka M., Hirose S., Kunou M., Akaike T. pH-sensing nano-crystals of carbonate apatite: effects on intracellular delivery and release of DNA for efficient expression into mammalian cells. Gene 2006, 376:87-94.
43. Kutsuzawa K., Akaike T., Chowdhury E.H. The influence of the cell adhesive proteins E-cadherin and fibronectin embedded in carbonate-apatite DNA carrier on transgene delivery and expression in a mouse embryonic stem cell line. Biomaterials 2008, 29:370-376.
44. Tada S., Chowdhury E.H., Cho C.S., Akaike T. pH-sensitive carbonate apatite as an intracellular protein transporter. Biomaterials 2010, 31:1453-1459.
45. Chowdhury E.H. pH-sensitive nano-crystals of carbonate apatite for smart and cell-specific transgene delivery. Expert Opin. Drug Deliv. 2007, 4:193-196.
46. Chowdhury E.H., Akaike T. pH-sensitive inorganic nano-particles and their precise cell targetibility: an efficient gene delivery and expression system. Curr. Chem. Biol. 2007, 1:201-213.
47. Chowdhury E.H., Akaike T. High performance DNA nano-carriers of carbonate apatite: multiple factors in regulation of particle synthesis and transfection efficiency. Int. J. Nanomedicine 2007, 2:101-106.
48. Chowdhury E.H. Self-assembly of DNA and cell-adhesive proteins onto pH-sensitive inorganic crystals for precise and efficient transgene delivery. Curr. Pharm. Des. 2008, 14:2212-2228.
49. Chowdhury E.H., Akaike T. Bio-functional inorganic materials: an attractive branch of gene-based nano-medicine delivery for 21st century. Curr. Gene Ther. 2005, 5:669-676.
50. Chowdhury E.H., Akaike T. A bio-recognition device developed onto nano-crystals of carbonate apatite for cell-targeted gene delivery. Biotechnol. Bioeng. 2005, 90:414-421.
51. Kamiya H., Akita H., Harashima H. Pharmacokinetic/pharmacodynamic considerations in gene therapy. Drug Discov. Today 2003, 8:990-996.
52. Khalil I.A., Kogure K., Akita H., Harashima H. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol. Rev. 2006, 58:32-45.
53. Friend D.S., Papahadjopoulos D., Debs R.J. Endocytosis and intracellular processing accompanying transfection mediated by cationic liposomes. Biochim. Biophys. Acta 1996, 1278:41-50.
54. Labat-Moleur F., Steffan A.M., Brisson C., Perron H., Feugeas O., Furstenberger P., Oberling F., Brambilla E., Behr J.P. An electron microscopy study into the mechanism of gene transfer with lipopolyamines. Gene Ther. 1996, 3:1010-1017.
55. Zuhorn I.S., Kalicharan R., Hoekstra D. Lipoplex-mediated transfection of mammalian cells occurs through the cholesterol-dependent clathrin-mediated pathway of endocytosis. J. Biol. Chem. 2002, 277:18021-18028.
56. Bally M.B., Harvie P., Wong F.M., Kong S., Wasan E.K., Reimer D.L. Biological barriers to cellular delivery of lipid-based DNA carriers. Adv. Drug Deliv. Rev. 1999, 38:291-315.
57. Porter L.A., Donoghue D.J. Cyclin B1 and CDK1: nuclear localization and upstream regulators. Prog. Cell Cycle Res. 2003, 5:335-347.
58. Miyazaki T., Arai S. Two distinct controls of mitotic cdk1/cyclin B1 activity requisite for cell growth prior to cell division. Cell Cycle 2007, 6:1419-1425.
59. Scherer L.J., Rossi J.J. Approaches for the sequence-specific knockdown of mRNA. Nat. Biotechnol. 2003, 21:1457-1465.